HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds
- PMID: 17269924
- DOI: 10.2174/138161207779313722
HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds
Abstract
HIV envelope glycoprotein transmembrane subunit gp41 plays a critical role in the fusion between viral and target cell membranes. Upon gp120 binding to CD4 and a coreceptor (CCR5 or CXCR4), gp41 changes its conformation by forming N-helix trimer between N-heptad repeats (NHRs) and then six-helix bundle between the N-trimer and the C-heptad repeats (CHRs). Peptides derived from the NHR and CHR of gp41 extracellular region have demonstrated potent inhibitory activity on the HIV mediated cell fusion. One of these peptides, T-20, became the first success of a new class of anti-HIV agents, named HIV entry inhibitors. However, a relatively long peptide such as T-20 suffers from several limitations including lack of oral bioavailability and high cost of production. Great efforts have been made to develop alternative peptides and proteins with improved anti-HIV-1 activity, increased bioavailability and reduced cost of production. The most promising approach is the development of small molecule HIV entry inhibitors targeting gp41. Any molecule that blocks the process of NHR homotrimerization and the six-helix bundle formation by targeting the gp41 NHR, NHR trimer and CHR may inhibit HIV-mediated membrane fusion. The progress in development of those anti-HIV agents targeting gp41, from polypeptides to small-molecule compounds, is reviewed.
Similar articles
-
High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques.Curr Pharm Des. 2004;10(15):1827-43. doi: 10.2174/1381612043384466. Curr Pharm Des. 2004. PMID: 15180543 Review.
-
ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer.Biochim Biophys Acta. 2014 May;1838(5):1296-305. doi: 10.1016/j.bbamem.2013.12.022. Epub 2014 Jan 3. Biochim Biophys Acta. 2014. PMID: 24388952
-
HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.J Formos Med Assoc. 2010 Feb;109(2):94-105. doi: 10.1016/S0929-6646(10)60029-0. J Formos Med Assoc. 2010. PMID: 20206833 Review.
-
Peptide and non-peptide HIV fusion inhibitors.Curr Pharm Des. 2002;8(8):563-80. doi: 10.2174/1381612024607180. Curr Pharm Des. 2002. PMID: 11945159 Review.
-
The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.J Virol. 2019 Dec 12;94(1):e01358-19. doi: 10.1128/JVI.01358-19. Print 2019 Dec 12. J Virol. 2019. PMID: 31619552 Free PMC article.
Cited by
-
Rationally designed inhibitors of the Musashi protein-RNA interaction by hotspot mimicry.Res Sq [Preprint]. 2023 Jan 10:rs.3.rs-2395172. doi: 10.21203/rs.3.rs-2395172/v1. Res Sq. 2023. PMID: 36711552 Free PMC article. Preprint.
-
Rationally designed inhibitors of the Musashi protein-RNA interaction by hotspot mimicry.bioRxiv [Preprint]. 2023 Jan 10:2023.01.09.523326. doi: 10.1101/2023.01.09.523326. bioRxiv. 2023. PMID: 36711508 Free PMC article. Preprint.
-
A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity.J Virol. 2021 Jul 12;95(15):e0235020. doi: 10.1128/JVI.02350-20. Epub 2021 Jul 12. J Virol. 2021. PMID: 33980592 Free PMC article.
-
Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19).Front Immunol. 2020 Jun 19;11:1451. doi: 10.3389/fimmu.2020.01451. eCollection 2020. Front Immunol. 2020. PMID: 32636851 Free PMC article. Review.
-
Molecular Characteristics, Functions, and Related Pathogenicity of MERS-CoV Proteins.Engineering (Beijing). 2019 Oct;5(5):940-947. doi: 10.1016/j.eng.2018.11.035. Epub 2019 Jul 17. Engineering (Beijing). 2019. PMID: 32288963 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials